Your browser doesn't support javascript.
loading
Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease.
Hemperly, Amy; Sandborn, William J; Vande Casteele, Niels.
Affiliation
  • Hemperly A; Department of Pediatric Gastroenterology, La Jolla, California.
  • Sandborn WJ; Department of Medicine, Division of Gastroenterology, University of California San Diego, La Jolla, California.
  • Vande Casteele N; Department of Pediatric Gastroenterology, La Jolla, California.
Inflamm Bowel Dis ; 24(12): 2527-2542, 2018 11 29.
Article de En | MEDLINE | ID: mdl-29788338
ABSTRACT
This review describes the clinical pharmacology of the major drugs used for the treatment of patients with inflammatory bowel disease (IBD). Pharmacokinetics, drug metabolism, mechanism of action, efficacy, and safety profile are discussed. Some small molecules were developed to act systemically (eg, ozanimod) or locally (eg, aminosalicylates) and thus have disparate pharmacokinetic properties. In addition, locally acting compounds have been optimized to mitigate systemic exposure-eg, budesonide, which undergoes extensive first-pass metabolism-thereby reducing systemic bioavailability and side effects. Other small molecules such as thiopurines are precursors of their active metabolites and differences in genotype or phenotype of metabolizing enzymes may affect efficacy and safety, requiring therapeutic drug monitoring (TDM). Monoclonal antibodies (MAs) are large molecules administered parenterally, and their pharmacokinetics may be influenced not only by the general immunoglobulin (Ig) G metabolism and recycling pathways but also by antigen properties such as antigen distribution and antigen concentration. In addition, antibody structure, host factors, concurrent medications, and immunogenicity may contribute to the substantial inter- and intrapatient variability in drug exposure and response observed for MAs. Current guidelines recommend reactive TDM of tumor necrosis factor antagonists at the time of loss of response. Evidence for proactive TDM and for the role of TDM for biologics with a different mechanism of action is emerging. Although small molecules offer potential benefits over biologics with oral administration and lack of immunogenicity, there may be risk for more systemic side effects due to off-target binding. Understanding drug metabolism, pharmacokinetic characteristics, and mechanism of action are important in selecting the right drug at the right time at the right dose for patients with IBD.10.1093/ibd/izy189_video1izy189.video15786062223001.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Produits biologiques / Agents gastro-intestinaux / Maladies inflammatoires intestinales / Surveillance des médicaments Type d'étude: Clinical_trials / Guideline / Systematic_reviews Limites: Adult / Child / Humans Langue: En Journal: Inflamm Bowel Dis Sujet du journal: GASTROENTEROLOGIA Année: 2018 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Produits biologiques / Agents gastro-intestinaux / Maladies inflammatoires intestinales / Surveillance des médicaments Type d'étude: Clinical_trials / Guideline / Systematic_reviews Limites: Adult / Child / Humans Langue: En Journal: Inflamm Bowel Dis Sujet du journal: GASTROENTEROLOGIA Année: 2018 Type de document: Article